$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo...
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target...
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global...
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable...
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.